Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY46GM
|
|||
| Drug Name |
Lefitolimod
|
|||
| Synonyms |
MGN1703
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 2 | [1] | |
| Company |
Mologen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03837756) Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN). U.S. National Institutes of Health. | |||
| REF 2 | Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.